Chicago Jury Finds AbbVie Fraudulently Marketed AndroGel to Injured Oregon Man; Awards $150 Million in Punitive Damages

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug. “This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. […]

July 24, 2017

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug.

“This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears it,” said MDL co-lead counsel Chris Seeger.  Mr. Mitchell is one of more than 4,000 plaintiffs who have sued AbbVie Inc. in the federal multidistrict litigation, In re: Testosterone Replacement Therapy Products Liability Litigation, case number 1:14-cv-01748, before Judge Matthew Kennelly in the U.S. District Court for the Northern District of Illinois. Mr. Mitchell claimed that AbbVie fraudulently misled doctors and patients about the drug’s benefits and risks—in particular, cardiovascular risks—when marketing the drug. The jury deliberated for 4 hours before reaching its verdict.  Partner Dave Buchanan, a member of the Mitchell trial team, commented, “For years before Jesse took AndroGel, AbbVie promoted unproven benefits and falsely assured doctors and patients about the safety of the drug.  The consequences of those acts are serious and real—facts that weren’t lost on this jury.”

Mr. Mitchell was represented by Troy Rafferty of Levin Papantonio, lead, David Buchanan of Seeger WeissBill Robins of Robins Cloud, Stephanie O’Connor of Douglas & London, and David Diamond of Goldberg & Osborne. The case is Mitchell et al. v. AbbVie Inc. et al., case number 1:14-cv-09178.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.

Related News

October 3, 2023
Seeger Weiss Announces $425 Million Settlement with AstraZeneca in Proton-Pump Inhibitor Litigation

Seeger Weiss is pleased to announce a landmark $425 million settlement with AstraZeneca Pharmaceuticals in the Proton-Pump Inhibitor Products Liability Litigation. This significant achievement comes on behalf of thousands of consumers who suffered kidney injuries while using proton-pump inhibitor (“PPI”) medications. Founding partner Chris Seeger serves as co-lead counsel with Stephanie O’Connor of Douglas & […]

Read More
October 2, 2023
Seeger Weiss Founder Chris Seeger Awarded Law360 MVP for Product Liability

Seeger Weiss is pleased to announce that founding partner Chris Seeger was honored with a Law360 2023 MVP award for his product liability practice. This prestigious accolade serves as a testament to Chris’ unyielding commitment to holding corporations accountable and pursuing justice for consumers harmed by defective products. Over the course of the past year, […]

Read More
September 22, 2023
Seeger Weiss Represents City of Chicago in New PCB Lawsuit Against Monsanto

Earlier this week, the City of Chicago filed a lawsuit against Monsanto and other chemical companies seeking damages for widespread contamination of its waterways caused by Polychlorinated biphenyls (PCBs), highly toxic and dangerous chemical compounds known to accumulate in the human body and cause serious health effects. Plaintiffs allege that Monsanto intentionally misled the public […]

Read More